Shanghai Hengrui Pharmaceutical Co., Ltd.

Jiangsu Hengrui Medicine Company Ltd.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Sichuan University

Sichuan Haisco Pharmaceutical Co., Ltd.

Jiangsu Hansoh Pharmaceuticals Co., Ltd.

Peng Cho Tang

Fanglong Yang

Yidong Su

Lei Zhang

Yang Wayne Wang

Hejun Lü

Fuqiang Zhao

Guangyuan Shen

Bin Wang

Fei Li

Hongbo Fei

Yiqian Chen

Tao Yang

Yang Chen

Takuya Matsumoto

Wei Zhang

Zhe Zhu

Hao Zheng

Jun Wang

Qing Dong

Li Ping Wang

Piaoyang Sun

Li Wang

Junfeng Wang

Lijun Chen

Ying Zhou

Nong Zhang

Hejun Lu

Jijun Yuan

Yang Wang

Jiang Fan

Dongliang Guan

Lu Xiao

Zhigang Lin

Wangyang Tu

Zongan Liang

Yulin Ji

Xiangqin Li

Yihua Du

Hu Feng

Jianghong Fu

Jialiang Yang

Yonggang Wei

Yali Li

Limin Zhang

Fan Li

Jindong Liang

Weimin Wang

Linlin Qin

Jianyu Liu

Fangqiong Li

Shenglan Wang

Huadong Luo

Minggang Ju

Guangtao Qian

Pingyan Bie

Lin Wu

Baolei Zhang

Guoliang Liu

Lei Ren

Songlin Wan

Xinfeng Luo

Shixu Yi

Jianhong Fu

A lung lobe contour extraction method aiming at DR radiography, which includes the steps: Obtain the representative lung lobe contour template through offline training; initialize the extraction system of contour lobe area in the chest DR radiography; According to dimension of DICOM image, conduct three-layer pyramid decomposition on the images; Use Gabor filter bank to rebuild pending images; Convert residual error of the rebuilt image by the Gabor filter into black and white image; Use Zhan-Suen refinement algorithm to refine the black and white image; Call every template of the offline training and use them as the convolution kernel operator, conduct convolution on the contour imagep; Filter the local optimum convolution value with optimum possibility from the convolution results and combine the evaluations; Generate the lung lobe contour shape in accordance with the upper and lower templates of optimum matching and its position.

Kind of lung lobe contour extraction method aiming at DR radiography

A DR radiography lung contour extraction method based on fully convolutional network, which includes the steps: Establish the fully convolutional network structure of lung contour segmentation; Conduct off-line training on the weighting parameters of the fully convolutional network; Read DR image and weighting parameters of the fully convolutional network; Input DR image into fully convolutional network and output segmentation results of image through network terminal with network layer-by-layer feedforward. Establish lung contour in accordance with segmentation results.

Kind of DR radiography lung contour extraction method based on fully convolutional network

A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof are described. 

Methods of using phthalazinone ketone derivatives

The present invention relates to a phenol derivative and the preparation method and use in medicine thereof, and particular to a phenol derivative represented by general formula (A) or a stereoisomer, a solvate, a metabolite, a prodrug, a pharmaceutically acceptable salt or a cocrystal thereof, a preparation method thereof, a pharmaceutical composition comprising the same, and use of the compound or composition of the present invention in the field of the central nervous system; wherein the definitions of substituents in general formula (A) are the same as those in the Description.

Phenol derivative and preparation method and use in medicine thereof

Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof

The pharmaceutically acceptable salts of bicycle-substituted pyrazolon azo derivatives represented by the general formula (I), their preparation methods, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor. The definitions of substituents in the general formula (I) are the same as the description. 

Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof

6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof are disclosed. Specifically, the present disclosure discloses novel 6-amino quinazoline or 3-cyano quinoline derivatives presented by general formula (I), or tautomers, enantiomers, diastereomers, racemates or pharmaceutically acceptable salts thereof, or metabolites, metabolic precursors or prodrugs thereof, and their uses as treatment agents especially as protein kinase inhibitors, in which each substitutent group of general formula (I) is as defined in the specification. 

6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof

The present invention relates to pyrrolo[3,2-c]pyridine-4-one 2-indolinone compounds of Formula (I) and their pharmaceutically acceptable salts thereof, wherein R, R2, R3, R4, R5, R6, R7, R8 X, Y andhave the meaning cited in the specification. Also disclosed are the pharmaceutical compositions containing the foregoing compounds, methods for the preparation and pharmaceutical use thereof, particularly as protein kinase inhibitors. Formula (I). 

Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed. 

Dihydropteridinone derivatives, preparation process and pharmaceutical use thereof

The pharmaceutically acceptable salts of bicyclo-substituted pyrazolon azo derivatives represented by the general formula (I), their preparation methods, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor. The definitions of substituents in the general formula (I) are the same as the description. 

C-aryl glucoside derivatives, preparation processes and pharmaceutical uses thereof are disclosed. In particular, C-aryl glucoside derivatives represented by formula (I), with each substituent defined in the application, pharmaceutically acceptable salts or stereoisomers thereof, their preparation methods, and pharmaceutical compositions containing the derivatives as well as their uses as therapeutic agents, particularly as sodium-dependent glucose cotransporter (SGLT)-1 inhibitors, are disclosed. 

C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof

Pharmaceutically acceptable salts of (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-formic acid, their preparation methods, compositions containing the said pharmaceutical salts and their use as medicaments, especially as dipeptidyl peptidase IV (DPP-IV) inhibitors are disclosed. Of the many acceptable salts, one example is the following. 

Salts of (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-trifluoromethyl-5,6,7,8-tetrahydroimidazo[1,5-a] pyrazine-1-carboxylic acid, preparation method and medical use thereof

Tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I), their preparation methods, pharmaceutical compositions containing the derivatives and uses thereof as medicaments, especially as dipeptidyl peptidase IV inhibitors, wherein the substituents of formula (I) are defined as same as the description. 

Tetrahydro-imidazo[1,5-&#x3b1;] pyrazine derivatives, preparation process and medicinal use thereof

The invention provides derivatives of azabicyclo alkane having formula (ID), and the method for making them, wherein each substitute in formula (ID) is same as defined in the description. 

Dicycloazaalkane derivatives, preparation processes and medical uses thereof

The bicyclo-substituted pyrazolon-azo derivatives of formula (I) or pharmaceutical acceptable salts, hydrates or solvates thereof, methods for their preparation, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor are disclosed. The definition of substituents in formula (I) are the same as defined in the description. 

Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof

Growing community of inventors

Shanghai, China

Peng Cho Tang